Ripretinib Dosage
Medically reviewed by Drugs.com. Last updated on Sep 23, 2022.
Applies to the following strengths: 50 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Gastrointestinal Stromal Tumor
Recommended dose: 150 mg orally once daily until disease progression or acceptable toxicity
Use: For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
Recommended dose reduction for adverse reactions: 100 mg orally once daily.
- Permanently discontinue treatment in patients who are unable to tolerate this dose.
PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME (PPES):
- Grade 2:
- Withhold treatment until Grade 1 or less or baseline. If recovered within 7 days, resume at same dose; otherwise resume at reduced dose.
- Consider re-escalating if maintained at Grade 1 or less or baseline for at least 28 days.
- If PPES recurs, withhold this drug until Grade 1 or less or baseline and then resume at a reduced dose regardless of time to improvement.
- Grade 3:
- Withhold treatment for at least 7 days or until Grade 1 or less or baseline (maximum 28 days). Resume at a reduced dose.
- Consider re-escalating if maintained at Grade 1 or less or baseline for at least 28 days.
HYPERTENSION:
- Grade 3:
- If symptomatic, withhold treatment until symptoms have resolved and blood pressure is controlled.
- If blood pressure is controlled to Grade 1 or less or baseline, resume at the same dose; otherwise, resume at a reduced dose.
- If Grade 3 hypertension recurs, withhold treatment until symptoms have resolved and blood pressure is controlled. Resume at a reduced dose.
- Grade 4:
- Permanently discontinue treatment.
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION:
- Grade 3 or 4:
- Permanently discontinue treatment.
ARTHRALGIA OR MYALGIA:
- Grade 2:
- Withhold treatment until Grade 1 or less or baseline. If recovered within 7 days, resume at same dose; otherwise resume at reduced dose.
- Consider re-escalating treatment if maintained at Grade 1 or less or baseline for at least 28 days.
- If arthralgia or myalgia recurs, withhold treatment until Grade 1 or less or baseline and then resume at a reduced dose regardless of time to improvement.
- Grade 3:
- Withhold treatment for at least 7 days or until Grade 1 or less or baseline (maximum of 28 days). Resume at a reduced dose.
- Consider re-escalating this drug if maintained at Grade 1 or less or baseline for at least 28 days.
OTHER ADVERSE REACTIONS:
- Grade 3 or 4:
- Withhold treatment until Grade 1 or less or baseline (maximum 28 days), and then resume at a reduced dose; otherwise, permanently discontinue.
- Consider re-escalating treatment if no recurrence of the adverse reaction for at least 28 days.
- If Grade 3 or 4 recurs, permanently discontinue treatment.
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- This drug may be taken with or without food.
- Tablets should be swallowed whole; do not crush, chew, or dissolve.
- This drug should be taken at the same time each day.
- A missed dose should be taken if less than 8 hours have passed since the missed scheduled dose.
- An additional dose should not be taken if vomiting occurs after taking. The next scheduled dose should be taken.
Storage requirements:
- Store in the original container at room temperature between 20C to 25C (68F to 77F).
Monitoring:
- Adverse reactions: See the warnings section for additional information.
Patient advice:
- Read the Patient Information Leaflet.
- Consult your healthcare provider if you are pregnant or planning to become pregnant. There is a potential risk to a developing fetus.
- Females of reproductive potential should use effective contraception during treatment and for one week after the last dose.
- Males with females of reproductive potential should use effective contraception during treatment and for one week after the last dose as this medication may impair fertility.
- Breastfeeding is not recommended during treatment and for one week after the last dose.
- Inform your healthcare provider of all concomitant medications.
- This medication contains lactose.
More about ripretinib
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.